SE435897B - Forfarande for tillverkning av en osmotiskt driven avgivningsanordning - Google Patents

Forfarande for tillverkning av en osmotiskt driven avgivningsanordning

Info

Publication number
SE435897B
SE435897B SE7803690A SE7803690A SE435897B SE 435897 B SE435897 B SE 435897B SE 7803690 A SE7803690 A SE 7803690A SE 7803690 A SE7803690 A SE 7803690A SE 435897 B SE435897 B SE 435897B
Authority
SE
Sweden
Prior art keywords
layer
microporous
cellulose
semipermeable
delivery device
Prior art date
Application number
SE7803690A
Other languages
English (en)
Swedish (sv)
Other versions
SE7803690L (sv
Inventor
F Theeuwes
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of SE7803690L publication Critical patent/SE7803690L/xx
Publication of SE435897B publication Critical patent/SE435897B/sv

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B32—LAYERED PRODUCTS
    • B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B23/00—Layered products comprising a layer of cellulosic plastic substances, i.e. substances obtained by chemical modification of cellulose, e.g. cellulose ethers, cellulose esters, viscose
    • B32B23/04—Layered products comprising a layer of cellulosic plastic substances, i.e. substances obtained by chemical modification of cellulose, e.g. cellulose ethers, cellulose esters, viscose comprising such cellulosic plastic substance as the main or only constituent of a layer, which is next to another layer of the same or of a different material
    • B32B23/08—Layered products comprising a layer of cellulosic plastic substances, i.e. substances obtained by chemical modification of cellulose, e.g. cellulose ethers, cellulose esters, viscose comprising such cellulosic plastic substance as the main or only constituent of a layer, which is next to another layer of the same or of a different material of synthetic resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B32—LAYERED PRODUCTS
    • B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B2250/00—Layers arrangement
    • B32B2250/02—2 layers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B32—LAYERED PRODUCTS
    • B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B2270/00—Resin or rubber layer containing a blend of at least two different polymers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B32—LAYERED PRODUCTS
    • B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B2305/00—Condition, form or state of the layers or laminate
    • B32B2305/02—Cellular or porous
    • B32B2305/026—Porous
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B32—LAYERED PRODUCTS
    • B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B2307/00—Properties of the layers or laminate
    • B32B2307/70—Other properties
    • B32B2307/726—Permeability to liquids, absorption
    • B32B2307/7265—Non-permeable
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B32—LAYERED PRODUCTS
    • B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B2317/00—Animal or vegetable based
    • B32B2317/18—Cellulose, modified cellulose or cellulose derivatives, e.g. viscose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Vascular Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Feeding, Discharge, Calcimining, Fusing, And Gas-Generation Devices (AREA)
  • Formation And Processing Of Food Products (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
SE7803690A 1977-04-07 1978-03-31 Forfarande for tillverkning av en osmotiskt driven avgivningsanordning SE435897B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/785,582 US4160452A (en) 1977-04-07 1977-04-07 Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina

Publications (2)

Publication Number Publication Date
SE7803690L SE7803690L (sv) 1978-10-08
SE435897B true SE435897B (sv) 1984-10-29

Family

ID=25135946

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7803690A SE435897B (sv) 1977-04-07 1978-03-31 Forfarande for tillverkning av en osmotiskt driven avgivningsanordning

Country Status (10)

Country Link
US (1) US4160452A (enExample)
JP (1) JPS6011887B2 (enExample)
AU (1) AU515935B2 (enExample)
CA (1) CA1098442A (enExample)
CH (1) CH636276A5 (enExample)
DE (1) DE2814709A1 (enExample)
FR (1) FR2386316A1 (enExample)
GB (1) GB1556149A (enExample)
IT (1) IT1109132B (enExample)
SE (1) SE435897B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0365947A1 (en) * 1988-10-26 1990-05-02 Dib Limited Novel dosage form
US5178868A (en) * 1988-10-26 1993-01-12 Kabi Pharmacia Aktiebolaq Dosage form

Families Citing this family (329)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4235236A (en) * 1979-02-12 1980-11-25 Alza Corporation Device for dispensing drug by combined diffusional and osmotic operations
US4312347A (en) * 1980-02-25 1982-01-26 Iowa State University Research Foundation, Inc. Positive pressure drug releasing device
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4344929A (en) * 1980-04-25 1982-08-17 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4309996A (en) * 1980-04-28 1982-01-12 Alza Corporation System with microporous releasing diffusor
US4298003A (en) * 1980-05-12 1981-11-03 Alza Corporation System for delivering agent at zero order rate with emerging agent below saturation
US4300558A (en) * 1980-07-18 1981-11-17 Alza Corporation Self-driven fluid dispenser
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4439194A (en) * 1981-09-08 1984-03-27 Merck & Co., Inc. Water and drug delivery system for suppository use
US4484921A (en) * 1982-02-01 1984-11-27 Alza Corporation Theophylline therapy utilizing osmotic delivery
US4439196A (en) * 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4475916A (en) * 1982-03-18 1984-10-09 Merck & Co., Inc. Osmotic drug delivery system
DK90883A (da) * 1982-03-18 1983-09-19 Merck & Co Inc Beholder til osmotisk afgivelse af et stof eller en stofblanding
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
AT396056B (de) * 1983-03-04 1993-05-25 Alza Corp Verfahren zur herstellung einer vorrichtung zur kontinuierlichen abgabe eines wirkstoffes, insbesondere eines arzneimittels an eine waesserige verwendungsumgebung
US4789516A (en) * 1983-04-15 1988-12-06 Damon Biotech, Inc Production of sustained released system
US4722937A (en) * 1984-06-29 1988-02-02 Joseph Jacob Antitoxin vaginal products and catamenials
US4722936A (en) * 1983-05-05 1988-02-02 Joseph Jacob Deodorization vaginal products and catamenials
US4585792A (en) * 1983-05-05 1986-04-29 Technology Unlimited Inc. Protective additive to vaginal products and catamenials
NZ206600A (en) * 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
US4747845A (en) * 1983-10-17 1988-05-31 Enquay Pharmaceutical Associates Synthetic resin matrix system for the extended delivery of drugs
US4627850A (en) * 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
US4692336A (en) * 1984-03-19 1987-09-08 Alza Corporation Self controlled release device for administering beneficial agent to recipient
US4678467A (en) * 1984-03-21 1987-07-07 Alza Corporation Dispenser comprising capsule with volume displacing member
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
DE3586445T2 (de) 1984-06-26 1993-01-14 Merck & Co Inc Kondensierte benzo-laktam-verbindungen und deren pharmazeutische zusammensetzungen.
US4693895A (en) * 1984-10-26 1987-09-15 Alza Corporation Colon delivery system
US4627851A (en) * 1984-10-26 1986-12-09 Alza Corporation Colonic-therapeutic delivery system
US4786500A (en) * 1986-06-26 1988-11-22 Alza Corporation Programmable agent delivery system
US4927632A (en) * 1986-06-26 1990-05-22 Alza Corporation Selective pulsed drug delivery system
US4715994A (en) * 1986-11-05 1987-12-29 Merck & Co., Inc. Novel antibacterial agents and potentiators of carbapenem antibiotics
US5143908A (en) * 1986-11-05 1992-09-01 Merck & Co., Inc. Antibacterial agents and potentiators of carbapenem antibiotics
US5099063A (en) * 1986-11-05 1992-03-24 Merck & Co., Inc. Certain phosphinic acid derivatives having antibacterial activity
US5041644A (en) * 1987-07-06 1991-08-20 Merck & Co., Inc. Peptide derivatives of β-chloro-L(Z)-dehydro-glutamic acid
JPS6413097A (en) * 1987-07-06 1989-01-17 Mitsubishi Chem Ind Phosphonic acid derivative
US4814183A (en) * 1987-08-31 1989-03-21 Merck & Co., Inc. Device for the controlled release of drugs with Donnan-like modulation by charged insoluble resins
US4795644A (en) * 1987-08-03 1989-01-03 Merck & Co., Inc. Device for pH independent release of drugs through the Donnan-like influence of charged insoluble resins
US4886668A (en) * 1987-09-24 1989-12-12 Merck & Co., Inc. Multiparticulate controlled porosity osmotic pump
US4880631A (en) * 1987-09-24 1989-11-14 Merck & Co., Inc. Controlled porosity osmotic pump
US4994273A (en) * 1987-11-02 1991-02-19 Merck & Co., Inc. Solubility modulated drug delivery device
US5030732A (en) * 1988-03-03 1991-07-09 Merck & Co., Inc. Aminoethylphosphinic acid derivatives
US4859470A (en) * 1988-06-02 1989-08-22 Alza Corporation Dosage form for delivering diltiazem
US4966769A (en) * 1988-06-02 1990-10-30 Alza Corporation Method for delivering dosage form for diltiazem
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5145990A (en) * 1988-10-28 1992-09-08 Merck & Co., Inc. Phosphorous containing dhp enzyme inhibitors
US5147867A (en) * 1988-10-28 1992-09-15 Merck & Co., Inc. Phosphorus containing enzyme inhibitors
US4962097A (en) * 1988-10-28 1990-10-09 Merck & Co., Inc. Method of treating bacterial infection with phosphorus containing DHP enzyme inhibitors
US5376383A (en) * 1988-11-21 1994-12-27 Merck & Co., Inc. Method for enhancing the lowering of plasma-cholesterol levels
US4997658A (en) * 1988-11-21 1991-03-05 Merck & Co., Inc. Method for enhancing the lowering of plasma cholesterol levels
US5002540A (en) * 1989-05-22 1991-03-26 Warren Kirschbaum Intravaginal device and method for delivering a medicament
US5089530A (en) 1990-08-03 1992-02-18 Merck & Co., Inc. Novel fermentation product with antiparasitic activity
EP0542926B1 (en) * 1990-08-07 1995-02-15 Pfizer Inc. Use of interfacially-polymerized membranes in delivery devices
SG84487A1 (en) 1991-04-17 2001-11-20 Merck & Co Inc Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a b-adrenergic antagonist
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6080428A (en) * 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6129930A (en) * 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6316443B1 (en) 1994-08-04 2001-11-13 Merck & Co., Inc. Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a β-adrenergic antagonist
US6348571B1 (en) 1994-09-12 2002-02-19 Northwestern University Corticotropin release inhibiting factor and methods of using same
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
US5767113A (en) * 1995-05-10 1998-06-16 The Salk Institute For Biological Studies Compounds useful for concurrently activating glucocorticoid-induced response and reducing multidrug resistance
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
EP0827402A2 (en) * 1995-05-17 1998-03-11 Cedars-Sinai Medical Center Compositions containing fatty acids for improving digestion and absorption in the small intestine
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US6558708B1 (en) 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
US5741815A (en) * 1995-06-02 1998-04-21 Lai; Ching-San Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
US5756540A (en) * 1995-06-02 1998-05-26 Mcw Research Foundation, Inc. Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
US6511811B1 (en) 1995-06-07 2003-01-28 The Regents Of The University Of California Protein kinase C antagonist related to insulin receptor
US6372713B1 (en) 1995-09-08 2002-04-16 The Board Of Trustees Of Northwestern University Anti-depressant effects of corticotropin release inhibiting factor
US5747532A (en) * 1995-11-21 1998-05-05 Medinox, Inc. Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
US6723531B2 (en) 1996-04-05 2004-04-20 The Salk Institute For Biological Studies Method for modulating expression of exogenous genes in mammalian systems, and products related thereto
US5922761A (en) * 1996-09-06 1999-07-13 Medinox, Inc. Methods for in vivo reduction of iron levels and compositions useful therefor
WO1998011066A1 (en) 1996-09-10 1998-03-19 Medinox, Inc. Polydithiocarbamate-containing macromolecules and the use thereof for therapeutic and diagnostic applications
US5858402A (en) * 1997-02-11 1999-01-12 Medinox, Inc. Methods for in vivo reduction of cyanide levels and compositions useful therefor
PT973499E (pt) * 1997-03-31 2003-12-31 Alza Corp Sistema de administracao difusor implantavel
US5916910A (en) * 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US5985592A (en) * 1997-06-05 1999-11-16 Dalhousie University Uses for pentoxifylline or functional derivatives/metabolites thereof
US5840721A (en) 1997-07-09 1998-11-24 Ontogen Corporation Imidazole derivatives as MDR modulators
US6797691B1 (en) * 1997-07-23 2004-09-28 Northwestern University Methods and compositions for inhibiting angiogenesis
US7105496B2 (en) * 1998-07-23 2006-09-12 Northwestern University Methods and compositions for inhibiting angiogenesis
AU9221898A (en) * 1997-09-09 1999-03-29 Alza Corporation Pharmaceutical coating composition and method of use
US7060734B1 (en) 1997-09-09 2006-06-13 Alza Corporation Pharmaceutical coating composition and method of use
US20030220234A1 (en) * 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
WO1999019295A1 (en) 1997-10-10 1999-04-22 Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting arginase activity
US6607751B1 (en) 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
JP2001519386A (ja) 1997-10-15 2001-10-23 トーマス・ジェファーソン・ユニバーシティ 哺乳動物における血管収縮または血管痙攣を予防または緩和するための一酸化窒素供与体組成物、方法、装置およびキット
US6750201B1 (en) * 1997-10-17 2004-06-15 The Trustees Of The University Of Pennsylvania Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator
US8524277B2 (en) * 1998-03-06 2013-09-03 Alza Corporation Extended release dosage form
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
EP1070084A4 (en) * 1998-03-16 2001-09-12 Ontogen Corp PIPERAZINE AS INHIBITORS OF FRUKTOSE-1,6-BISPHOSPHATASE (FBPASE)
US6287605B1 (en) * 1998-04-17 2001-09-11 The Trustees Of The University Of Pennsylvania Compositions and methods useful in treatment and prevention of HIV-1 infection
WO1999058640A2 (en) 1998-05-11 1999-11-18 Philadelphia Health And Education Corporation Mct-1, a human oncogene
US6333318B1 (en) 1998-05-14 2001-12-25 The Salk Institute For Biological Studies Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
US20050203187A1 (en) * 1998-06-01 2005-09-15 Verbiscar Anthony J. Formulations useful for the treatment of varicella zoster virus infections and methods for the use thereof
US6265420B1 (en) 1998-06-23 2001-07-24 Medinox, Inc. Use of nitric oxide scavengers to treat side effects caused by therapeutic administration of sources of nitric oxide
US6093743A (en) * 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US6596770B2 (en) 2000-05-05 2003-07-22 Medinox, Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US20030064917A1 (en) * 1998-07-23 2003-04-03 Crawford Susan E. Methods and compositions for inhibiting angiogenesis
US6565854B2 (en) 1998-08-13 2003-05-20 Philadelphia Health And Education Corporation Antimicrobial histone H1 compositions, kits, and methods of use thereof
WO2000009118A1 (en) 1998-08-13 2000-02-24 The Wistar Institute Methods for reducing atherosclerotic plaques
US6646113B1 (en) * 1998-09-17 2003-11-11 The Trustees Of The University Of Pennsylvania Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants
US7906143B1 (en) 1998-10-05 2011-03-15 Intellipharmaceutics Corp Controlled release pharmaceutical delivery device and process for preparation thereof
US20020138856A1 (en) * 1998-10-23 2002-09-26 Northwestern University Compositions and methods useful for treatment of depressive disorder based on an animal model
NZ512676A (en) 1999-01-13 2003-01-31 Meditech Res Ltd A composition and method for the enhancement of the efficacy of drugs
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
AU2732000A (en) 1999-01-19 2000-08-01 Children's Hospital Of Philadelphia, The Reverse gene therapy
US7282489B2 (en) * 2000-01-19 2007-10-16 The Children's Hospital Of Philadelphia Compositions and methods for performing reverse gene therapy
US7141417B1 (en) * 1999-02-25 2006-11-28 Thomas Jefferson University Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene
US6221855B1 (en) 1999-03-11 2001-04-24 Wake Forest University Regulation of nucleic acid expression by heparan sulfate and biological equivalents thereof
US6428968B1 (en) 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6025502A (en) * 1999-03-19 2000-02-15 The Trustees Of The University Of Pennsylvania Enantopselective synthesis of methyl phenidate
US6251927B1 (en) 1999-04-20 2001-06-26 Medinox, Inc. Methods for treatment of sickle cell anemia
EP1180114B1 (en) 1999-04-27 2011-09-21 The Trustees of The University of Pennsylvania Use of resisitin specific antibodies in the treatment of diabetes
US6420545B1 (en) * 1999-05-24 2002-07-16 The Trustees Of The University Of Pennsylvania CD4-independent HIV envelope proteins as vaccines and therapeutics
US7160694B2 (en) 1999-06-14 2007-01-09 Millennium Pharmaceuticals, Inc. Nucleic acids encoding TANGO405 and functional fragments and uses thereof
US7033780B1 (en) * 1999-06-14 2006-04-25 Millennium Pharmaceuticals, Inc. Nucleic acids corresponding to TANGO 294 a gene encoding a lipase—like protein
US6964854B1 (en) 1999-07-13 2005-11-15 Science & Technology Corporation Compositions and methods useful for the diagnosis and treatment of heparin induced thrombocytopenia/thrombosis
AU782401B2 (en) 1999-10-08 2005-07-28 Taiji Biomedical, Inc. Methods of enhancing chemotherapy
US20020147197A1 (en) * 1999-10-08 2002-10-10 Newman Michael J. Methods and compositions for enhancing pharmaceutical treatments
US6274627B1 (en) 1999-10-12 2001-08-14 Medinox, Inc. Conjugates of dithiocarbamate disulfides with pharmacologically active agents and uses therefor
US7057015B1 (en) 1999-10-20 2006-06-06 The Salk Institute For Biological Studies Hormone receptor functional dimers and methods of their use
US6559128B1 (en) 2000-01-21 2003-05-06 Northwestern University Inhibitors of G protein-mediated signaling, methods of making them, and uses thereof
US20030212021A1 (en) * 2001-01-25 2003-11-13 Frost Gregory I. Myeloid colony stimulating factor and uses thereof
US6464688B1 (en) 2000-02-15 2002-10-15 Microsolutions, Inc. Osmotic pump delivery system with flexible drug compartment
US6569152B2 (en) * 2000-03-21 2003-05-27 Farrington Pharmaceuticals, Llc Sustained release delivery systems for solutes
RU2323000C2 (ru) * 2000-04-07 2008-04-27 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Аналоги тамандарина и дидемнина и способы их получения и применения
US6509315B1 (en) * 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
AU2001269803A1 (en) * 2000-06-20 2002-01-02 The Trustees Of The University Of Pennsylvania Compositions and methods for modulating muscle cell and tissue contractility
US6429223B1 (en) 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
EP1303536B1 (en) 2000-07-19 2010-03-17 Advanced Research And Technology Institute, Inc. Novel fibroblast growth factor (fgf23) and methods for use
AU2001290629A1 (en) * 2000-09-07 2002-03-22 Boehringer Ingelheim International G.M.B.H Heat shock response and virus replication
AU2001296915A1 (en) * 2000-09-26 2002-04-08 Sidney Kimmel Cancer Center Inhibition of antigen presentation with poorly catabolized polymers
US20030195706A1 (en) * 2000-11-20 2003-10-16 Michael Korenberg Method for classifying genetic data
US20030175349A1 (en) * 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
US20040102367A1 (en) * 2001-02-23 2004-05-27 Gage Fred H Gene expression system based on chimeric receptors
US7208279B2 (en) * 2001-03-14 2007-04-24 Caden Biosciences, Inc. Method for identifying inhibitors of G protein coupled receptor signaling
US7294472B2 (en) * 2001-03-14 2007-11-13 Caden Biosciences Method for identifying modulators of G protein coupled receptor signaling
US6727287B2 (en) 2001-04-16 2004-04-27 Pts International, Inc. Toluene sulfonamide-containing anti-tumor composition and method of use thereof
US6632217B2 (en) 2001-04-19 2003-10-14 Microsolutions, Inc. Implantable osmotic pump
CN1157388C (zh) * 2001-05-29 2004-07-14 北京大学 哌嗪基二硫代甲酸酯类化合物,它们的制备方法和在抗肿瘤药物中的应用
US7883717B2 (en) 2001-06-12 2011-02-08 Johns Hopkins University Reservoir device for intraocular drug delivery
RU2259825C9 (ru) 2001-06-18 2006-04-10 БиоДием Лимитед Вещества, проявляющие антимикробную, антигрибковую, антипротозойную активности
US6884619B2 (en) 2001-07-17 2005-04-26 Yale University Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors
AU2002322515A1 (en) * 2001-07-17 2003-03-03 Keith Choate Compositions, methods, and kits related to treating and diagnosing hypertension
US9056048B2 (en) * 2001-08-16 2015-06-16 The Trustees Of The University Of Pennsylvania Synthesis and use of cationic steroids for anti-inflammatory drug therapy
ATE468861T1 (de) * 2001-08-16 2010-06-15 Univ Pennsylvania Synthese und verwendung von reagenzien für die verbesserte dna-lipofektion und/oder prodrug- und arzneimitteltherapien mit langsamer freisetzung
JP2005505540A (ja) * 2001-08-27 2005-02-24 メディテック　リサーチ　リミテッド 改善された治療プロトコール
SI1436321T1 (sl) * 2001-10-19 2006-12-31 Isotechnika Inc Sinteza analogov ciklosporina
US6555563B1 (en) 2001-11-16 2003-04-29 Medinox, Inc. Heteroaryl substituted amidinyl and imidazolyl compounds and methods employing same for the treatment of inflammation
EP1499289B1 (en) * 2002-03-29 2008-07-23 Alza Corporation Volume efficient controlled release dosage form
US7622117B2 (en) * 2002-04-17 2009-11-24 Dynamis Therapeutics, Inc. 3-deoxyglucosone and skin
US20030232741A1 (en) * 2002-05-06 2003-12-18 Washington University Methods of treatment of glaucoma and other conditions mediated by NOS-2 expression via inhibition of the EGFR pathway
US20080051428A1 (en) * 2002-05-15 2008-02-28 Davis Paul J Pyrroloquinoline quinone drugs and methods of use thereof
AUPS234402A0 (en) * 2002-05-15 2002-06-13 Auckland Uniservices Limited Anti-tumour polycyclic carboxamides
US20040077691A1 (en) * 2002-06-21 2004-04-22 Medinox, Inc. Hydroxamate derivatives of non-steroidal anti-inflammatory drugs
US6620813B1 (en) 2002-06-21 2003-09-16 Medinox, Inc. Hydroxamate derivatives of non-steroidal anti-inflammatory drugs
EP1558585B1 (en) 2002-10-04 2013-09-25 Prana Biotechnology Limited Neurologically-active compounds
WO2004037206A2 (en) * 2002-10-23 2004-05-06 University Of Hawaii Methods for diagnosing and treating pre-term labor
US20050143449A1 (en) * 2002-11-15 2005-06-30 The Salk Institute For Biological Studies Non-steroidal farnesoid X receptor modulators and methods for the use thereof
JP2006518191A (ja) * 2003-01-09 2006-08-10 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア 細菌ワクチンベクターの免疫原性を強化するための組成物、方法、及びキット
AU2003900927A0 (en) * 2003-02-28 2003-03-13 Biodiem Ltd Growth promotion method
US7919178B2 (en) * 2003-03-21 2011-04-05 Millipore Corporation Spatially-controlled modified porous membrane
EP1613338A4 (en) * 2003-03-21 2009-06-24 Madeleine M Joullie TAMANDARIN ANALOGUES, FRAGMENTS THEREOF AND METHODS OF MAKING AND USING THE SAME
AU2004249295A1 (en) * 2003-06-20 2004-12-29 Viral Genomix, Inc. Compositions for and methods for treating HIV
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US8071535B2 (en) * 2003-09-12 2011-12-06 The Regents Of The University Of California Guanidinium derivatives for improved cellular transport
WO2005033297A1 (en) * 2003-09-19 2005-04-14 The Rockefeller University Compositions, methods and kits relating to reprogramming adult differentiated cells and production of embryonic stem cell-like cells
US20050129764A1 (en) * 2003-12-11 2005-06-16 Vergez Juan A. Osmotic device containing licofelone
AU2005223847A1 (en) 2004-03-19 2005-09-29 Yale University Detection, isolation and uses of renalase (Monoamine Oxidase C)
JP4991527B2 (ja) 2004-06-01 2012-08-01 ユニバーシティ オブ バージニア パテント ファンデーション 二つの部分からなる低分子量の癌および血管新生の抑制剤
US7740861B2 (en) * 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
US8507411B2 (en) * 2004-06-24 2013-08-13 Wisconsin Alumni Research Foundation Neoglycorandomization and digitoxin analogs
CA2571409C (en) * 2004-06-24 2012-01-24 Wisconsin Alumni Research Foundation Neoglycorandomization and digitoxin analogs
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
ES2375995T3 (es) 2004-09-17 2012-03-08 University Of Massachusetts Composiciones y sus usos para deficiencias de enzima lisosomal.
JP2008514709A (ja) * 2004-10-01 2008-05-08 メルク エンド カムパニー インコーポレーテッド 眼科疾患を治療するための組成物および方法
US7744556B2 (en) * 2005-03-25 2010-06-29 Kimberly-Clark Worldwide, Inc. Delivery tube assembly for an applicator
US7993667B2 (en) * 2005-03-25 2011-08-09 Kimberly-Clark Worldwide, Inc. Methods of manufacturing a medicated tampon assembly
US7527614B2 (en) * 2005-03-25 2009-05-05 Kimberly-Clark Worldwide, Inc. Protective tube for a medicated tampon
US7919453B2 (en) * 2005-03-25 2011-04-05 Kimberly-Clark Worldwide, Inc. Dosage cap assembly for an applicator
US9295289B2 (en) * 2005-04-01 2016-03-29 Leslie Jane James Waist-fastening, hip-encompassing apparel with at least one concealed storage compartment
US7708726B2 (en) * 2005-04-28 2010-05-04 Kimberly-Clark Worldwide, Inc. Dosage form cap for an applicator
WO2006127361A2 (en) 2005-05-23 2006-11-30 Sdg, Inc. Lipid construct for delivery of insulin to a mammal
WO2006138609A2 (en) * 2005-06-17 2006-12-28 Dynamis Therapeutics, Inc. Treatment of inflammatory conditions
MX2007016270A (es) 2005-06-27 2008-03-05 Amgen Inc Compuestos aril nitrilo anti-inflamatorios.
JP5465431B2 (ja) * 2005-07-27 2014-04-09 アルケミア オンコロジー ピーティーワイ リミテッド ヒアルロナンを用いる治療プロトコル
US20070036929A1 (en) * 2005-08-09 2007-02-15 The Boeing Company Thin film applique
CA2620306A1 (en) 2005-08-25 2007-03-01 Repair Technologies, Inc. Devices, compositions and methods for the protection and repair of cells and tissues
US8871764B2 (en) 2005-08-29 2014-10-28 University Of Virginia Patent Foundation Lisofylline analogs and methods for use
DK1919867T3 (da) * 2005-08-29 2011-12-12 Univ Virginia Patent Found Lisofyllinanaloger og farmaceutiske anvendelser heraf
CN101287475B (zh) 2005-09-07 2012-11-14 阿尔卡米亚肿瘤学股份有限公司 包含透明质酸和治疗抗体的治疗组合物以及制药用途
EP1956906A4 (en) 2005-11-09 2009-12-30 Combinatorx Inc METHODS, COMPOSITIONS AND KITS FOR THE TREATMENT OF PATHOLOGIES
US20070141118A1 (en) * 2005-12-15 2007-06-21 Damico Joyce A Layered dosage form for a medicated tampon assembly
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
EP1996176B1 (en) * 2006-02-21 2010-05-19 Astrum Therapeutics Pty, Ltd. Compositions to reduce blood glucose levels and treat diabetes
CA2648280C (en) 2006-04-03 2014-03-11 Isa Odidi Controlled release delivery device comprising an organosol coat
ES2437997T3 (es) 2006-04-14 2014-01-15 Prana Biotechnology Limited Método de tratamiento de la degeneración macular relacionada con la edad (AMD)
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
WO2008030618A1 (en) 2006-09-07 2008-03-13 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
US8232254B2 (en) * 2006-10-06 2012-07-31 Wisconsin Alumni Research Foundation Colchicine neoglycosides and methods for their synthesis and use
WO2008045484A1 (en) 2006-10-10 2008-04-17 Amgen Inc. N-aryl pyrazole compounds for use against diabetes
MX2009006672A (es) 2006-12-19 2009-10-26 Univ Virginia Efectos combinados de topiramato y ondansetron sobre el consumo de alcohol.
US20100221337A1 (en) * 2007-02-14 2010-09-02 Logical Therapeutics, Inc. Method of treating arthritis, pain or inflammation with naproxen 2(methanesulfonyl)ethyl ester and an h2 receptor antagonist
CA2679301C (en) 2007-02-28 2015-08-11 University Of Virginia Patent Foundation Lisofylline analogs and methods for use in protecting pancreatic .beta.-cells, treating type 1 diabetes, and treating inflammatory and autoimmune diseases
US20100221334A1 (en) * 2007-07-19 2010-09-02 Fink Mitchell P Compositions including leukotriene antagonists and nsaids and methods of using the same
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
US8846053B2 (en) 2008-09-26 2014-09-30 Sdg, Inc. Orally bioavailable lipid-based constructs
US8779002B2 (en) 2007-10-15 2014-07-15 Salk Institute For Biological Studies Methods for treating a variety of diseases and conditions, and compounds useful therefor
US8389485B2 (en) * 2007-10-29 2013-03-05 University Of Massachusetts Encapsulated nanoparticles for nucleic acid delivery
CN102137836B (zh) 2008-07-28 2015-08-26 赛丹思科大学 用于治疗代谢疾病的化合物
AU2010208046B2 (en) 2009-01-29 2014-10-02 Forsight Vision4, Inc. Posterior segment drug delivery
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US8785468B2 (en) 2009-02-13 2014-07-22 Amgen Inc. Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
JP2012526133A (ja) 2009-05-05 2012-10-25 ベイポジェニックス インコーポレイテッド 炎症を低減させるための新規揮発性麻酔薬製剤およびその使用法
CN104887388B (zh) 2009-06-03 2018-01-09 弗赛特影像5股份有限公司 前段药物输送
US20110045522A1 (en) * 2009-08-20 2011-02-24 Danchen Gao Methods for diagnosing diabetes and determining effectiveness of treatments
WO2011034951A2 (en) 2009-09-15 2011-03-24 The Regents Of The University Of California Assisted enzyme replacement therapy
CA2829790C (en) 2010-03-30 2018-06-05 Verseon Corporation Multisubstituted aromatic compounds as inhibitors of thrombin
US9193989B2 (en) 2010-06-18 2015-11-24 Taiho Pharmaceutical Co., Ltd. PRPK-TPRKB modulators and uses thereof
NZ621352A (en) 2010-07-02 2015-08-28 Univ Virginia Patent Found Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
HUE054113T2 (hu) 2010-08-05 2021-08-30 Forsight Vision4 Inc Injekciós készülék gyógyszerbejuttatáshoz
EP2600876B1 (en) 2010-08-05 2015-04-29 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
HRP20211909T1 (hr) 2010-08-05 2022-03-18 Forsight Vision4, Inc. Uređaj za liječenja oka
US9000046B2 (en) 2010-09-28 2015-04-07 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
CA2819230A1 (en) 2010-10-28 2012-05-03 Yale University Methods and compositions for assessing and treating cancer
US20140031769A1 (en) 2010-11-19 2014-01-30 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP2643470B1 (en) 2010-11-24 2016-02-03 Yale University Compositions and methods for treating ischemic injury with d-dt
WO2012078633A2 (en) 2010-12-07 2012-06-14 Philadelphia Health And Education Corporation, D/B/A Drexel University College Of Medicene Methods of inhibiting metastasis from cancer
TR201900128T4 (tr) 2010-12-15 2019-02-21 Contravir Pharmaceuticals Inc Amino asit 1'de ve 3'te modifiye edilmiş siklosporin analoğu moleküller.
WO2012138706A1 (en) 2011-04-06 2012-10-11 Mcw Research Foundation, Inc. Epoxyeicosatrienoic acid analogs and methods of making and using the same
US8476221B2 (en) 2011-03-18 2013-07-02 Halimed Pharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders
KR20160035613A (ko) 2011-03-23 2016-03-31 암젠 인크 Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제
CN104470886A (zh) 2011-04-08 2015-03-25 赛丹思科大学 用于治疗代谢疾病的邻-氟取代的化合物
CA2835018C (en) 2011-05-04 2020-04-21 Balance Therapeutics, Inc. Pentylenetetrazole derivatives
US20140161827A1 (en) 2011-05-09 2014-06-12 University Of Virginia Patent Foundation Compositions and methods for treating cancer
US10398592B2 (en) 2011-06-28 2019-09-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
US10702485B2 (en) 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol
EP2739252A4 (en) 2011-08-05 2015-08-12 Forsight Vision4 Inc SMALL MOLECULE ADMINISTRATION USING AN IMPLANTABLE THERAPEUTIC DEVICE
WO2013036290A1 (en) 2011-09-09 2013-03-14 Yale University Compositions and methods for assessing and treating inflammatory diseases and disorders
EP2751137A4 (en) 2011-09-09 2015-06-03 Univ Virginia Patent Found MOLECULAR GENETIC APPROACH FOR THE TREATMENT AND DIAGNOSIS OF ALCOHOL AND DRUG INDEPENDENCE
EP2755615B1 (en) 2011-09-14 2022-04-06 Forsight Vision5, Inc. Ocular insert apparatus
EP4643921A2 (en) 2011-09-16 2025-11-05 ForSight Vision4, Inc. Fluid exchange apparatus
US20130128908A1 (en) 2011-11-18 2013-05-23 Laser Energetics Inc. Diode pumped solid state opto-mechanically optimized green laser
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
EP2950790A4 (en) 2012-08-09 2018-04-25 Dynamis Therapeutics, Inc. Methods for maintaining or improving health, well-being and/or a physiological function in a subject
WO2014036022A1 (en) 2012-08-29 2014-03-06 Amgen Inc. Quinazolinone compounds and derivatives thereof
SI2911623T1 (sl) 2012-10-26 2019-12-31 Forsight Vision5, Inc. Oftalmični sistem za podaljšano sproščanje zdravila v oko
ES2955137T3 (es) 2013-03-14 2023-11-28 Alkermes Pharma Ireland Ltd Profármacos de fumaratos y su uso en el tratamiento de diversas enfermedades
EP2968113B8 (en) 2013-03-14 2020-10-28 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
CA2902431A1 (en) 2013-03-15 2014-09-25 Kevin Michael Short Halogenopyrazoles as inhibitors of thrombin
EP3421036B8 (en) 2013-03-15 2020-12-30 Verseon International Corporation Multisubstituted aromatic compounds as serine protease inhibitors
CN105246438B (zh) 2013-03-28 2018-01-26 弗赛特影像4股份有限公司 用于输送治疗物质的眼科植入物
AU2014284267B2 (en) 2013-07-02 2018-05-10 Ecoplanet Environmental Llc Volatile organic compound formulations having antimicrobial activity
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
TWI611802B (zh) 2013-10-23 2018-01-21 善笙生物科技股份有限公司 來自牛樟芝菌絲體的化合物及混合物的用途
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US9908923B2 (en) 2014-06-11 2018-03-06 The Medical College Of Wisconsin, Inc. Monomeric CXCL121 peptide and methods of use thereof
JO3394B1 (ar) 2014-07-04 2019-10-20 Osteo Pharma B V تركيبات ومنتجات للاستعمال في علاج كسور وعيوب العظام
EP3169289B1 (en) 2014-07-15 2020-04-15 ForSight Vision4, Inc. Ocular implant delivery device
MX2017001818A (es) 2014-08-08 2017-05-30 Forsight Vision4 Inc Formulaciones estables y solubles de inhibidores de receptor de quinasa tirosina y metodos de preparacion de los mismos.
RU2017112739A (ru) 2014-09-17 2018-10-17 Версеон Корпорейшн Пиразолил-замещенные пиридоновые соединения как ингибиторы сериновых протеаз
MX383085B (es) 2014-11-10 2025-03-13 Forsight Vision4 Inc Dispositivo de entrega de fármacos expandibles y método de uso.
EA031505B1 (ru) 2014-12-02 2019-01-31 Прана Байотекнолоджи Лимитед СОЕДИНЕНИЯ 4Н-ПИРИДО[1,2-а]ПИРИМИДИН-4-ОНА
DK3230255T3 (da) 2014-12-09 2020-06-22 Ezekiel Golan Regulatorer af uhæmmet adfærd
SG11201706411YA (en) 2015-02-27 2017-09-28 Verseon Corp Substituted pyrazole compounds as serine protease inhibitors
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
WO2016187408A1 (en) 2015-05-19 2016-11-24 Yale University Compositions for treating pathological calcification conditions, and methods using same
TN2017000483A1 (en) 2015-05-20 2019-04-12 Amgen Inc Triazole agonists of the apj receptor.
US11571462B2 (en) 2015-06-03 2023-02-07 The Medical College Of Wisconsin, Inc. Engineered CCL20 locked dimer polypeptide
US10738095B2 (en) 2015-06-03 2020-08-11 The Medical College Of Wisconsin, Inc. Engineered CCL20 locked dimer polypeptide
JP6871919B2 (ja) 2015-06-16 2021-05-19 ナノファギックス エルエルシー 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法
US10294228B2 (en) 2015-06-30 2019-05-21 Neurad Ltd. Breathing control modulating compounds, and methods of making and using same
WO2017079260A1 (en) 2015-11-02 2017-05-11 University Of Rochester Phosphonate-chloroquine conjugates and methods using same
WO2017079262A1 (en) 2015-11-02 2017-05-11 University Of Rochester Bortezomib conjugates and methods using same
WO2017087936A1 (en) 2015-11-20 2017-05-26 Yale University Compositions for treating ectopic calcification disorders, and methods using same
CA3005238A1 (en) 2015-11-20 2017-05-26 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
KR20180133440A (ko) 2016-04-05 2018-12-14 포사이트 비젼4, 인크. 이식 가능한 안구 약물 전달 장치
US10946020B2 (en) 2016-04-06 2021-03-16 University Of Virginia Patent Foundation Compositions and methods for treating cancer
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
KR102034697B1 (ko) 2016-06-03 2019-10-22 노바사이트, 인코포레이티드 폴리머 링커 및 이의 용도
WO2018026764A1 (en) 2016-08-01 2018-02-08 University Of Rochester Nanoparticles for controlled release of anti-biofilm agents and methods of use
US10449230B2 (en) 2016-10-06 2019-10-22 The Regents Of The University Of California Polymyxin derived cell penetrating scaffolds
KR102522060B1 (ko) 2016-11-07 2023-04-14 아뷰터스 바이오파마 코포레이션 치환된 피리디논 함유 트리시클릭 화합물, 및 그의 사용 방법
MA46827A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
WO2018097945A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
WO2018093580A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
US11191762B2 (en) 2016-11-16 2021-12-07 Amgen Inc. Alkyl substituted triazole compounds as agonists of the APJ Receptor
WO2018106928A1 (en) 2016-12-08 2018-06-14 Contravir Pharmaceuticals, Inc. Treatment and prevention of hbv diseases by cyclosporine analogue molecules modified at amino acides 1 and 3
CA3056886A1 (en) 2017-03-21 2018-09-27 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
WO2018191579A1 (en) 2017-04-14 2018-10-18 Contravir Pharmaceuticals, Inc. Combination therapy for treating viral infections
DE202017002464U1 (de) 2017-05-09 2017-06-12 St. Lotus Biotech Corp. Pflanzliche Zusammensetzung zur Vorbeugung oder Linderung von ischämischem Schlaganfall
EP3625248A4 (en) 2017-05-18 2021-01-20 The Rockefeller University COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH KCNJ5 MUTANT
WO2019089335A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Fused triazole agonists of the apj receptor
AU2018372806B2 (en) 2017-11-21 2024-05-30 Forsight Vision4, Inc. Fluid exchange apparatus for expandable port delivery system and methods of use
US20200323895A1 (en) 2017-11-27 2020-10-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Compounds, Compositions, and Methods for Treating And/Or Preventing Periodontal Disease
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
JP2021525269A (ja) 2018-05-29 2021-09-24 セルシィ セラピューティクス，インコーポレーテッド 疼痛処置のための化合物、それを含む組成物及びそれを使用する方法
WO2019236984A1 (en) 2018-06-08 2019-12-12 The Medical College Of Wisconsin, Inc. Methods of treating vascular leakage using cxcl12 peptides
TWI826492B (zh) 2018-07-27 2023-12-21 加拿大商愛彼特生物製藥公司 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
WO2020049505A1 (en) 2018-09-06 2020-03-12 Innopharmascreen Inc. Methods and compositions for treatment of asthma or parkinson's disease
TW202415643A (zh) 2018-12-12 2024-04-16 加拿大商愛彼特生物製藥公司 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
US20200246316A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
US20200246317A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
US11000488B2 (en) 2019-03-22 2021-05-11 Syntrix Biosystems Inc. Treating pain using desmetramadol
US11471507B2 (en) 2019-05-09 2022-10-18 The Feinstein Institutes For Medical Research HMGB1 antagonist
WO2021123394A1 (en) 2019-12-20 2021-06-24 University Of Copenhagen G protein-coupled receptor modulators and a pharmaceutical composition
AU2021262813A1 (en) 2020-04-30 2022-11-03 Annette M. TOBIA Compositions and methods for treating cytokine storms
EP4228675A1 (en) 2020-10-13 2023-08-23 Betavive Ltd. Method and compounds for treating diabetes and associated metabolic diseases
AU2022217475A1 (en) 2021-02-08 2023-08-24 Bausch Health Ireland Limited Amiselimod for preventing, treating, or ameliorating ulcerative colitis
WO2022263676A1 (en) 2021-06-18 2022-12-22 University Of Copenhagen Polysubstituted 4-hydroxypyridine and 4-hydroxyquinoline derivatives as gpr84 antagonists
MX2024004398A (es) 2021-10-12 2024-07-09 Betavive Ltd Peptidos y fragmentos para tratar diabetes y enfermedades metabolicas asociadas.
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device
WO2024052895A1 (en) 2022-09-06 2024-03-14 Hadasit Medical Research Services And Development Ltd Combinations comprising psychedelics for the treatment of schizophrenia and other neuropsychiatric and neurologic disorders
TW202513071A (zh) 2023-08-14 2025-04-01 以色列商琉璃藥品 (1991) 有限公司 Gal475組合物及其使用方法
WO2025064408A1 (en) 2023-09-18 2025-03-27 The Broad Institute, Inc. Compositions and methods for treating cardiovascular disease
WO2025099725A1 (en) 2023-11-09 2025-05-15 Hadasit Medical Research Services And Development Ltd. Conjugates and uses thereof
WO2025134072A1 (en) 2023-12-21 2025-06-26 Bausch Health Ireland Limited Methods for preventing, treating, or ameliorating ulcerative colitis in certain patient populations with amiselimod
WO2025219976A1 (en) 2024-04-19 2025-10-23 Betavive Ltd. Peptides and fragments for treating diabetes and associated metabolic diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3981303A (en) * 1971-09-09 1976-09-21 Alza Corporation Bioerodible ocular device
US3828777A (en) * 1971-11-08 1974-08-13 Alza Corp Microporous ocular device
US3948254A (en) * 1971-11-08 1976-04-06 Alza Corporation Novel drug delivery device
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4036227A (en) * 1973-04-25 1977-07-19 Alza Corporation Osmotic releasing device having a plurality of release rate patterns
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3995632A (en) * 1973-05-04 1976-12-07 Alza Corporation Osmotic dispenser
US3961628A (en) * 1974-04-10 1976-06-08 Alza Corporation Ocular drug dispensing system
US3977404A (en) * 1975-09-08 1976-08-31 Alza Corporation Osmotic device having microporous reservoir
US4014334A (en) * 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0365947A1 (en) * 1988-10-26 1990-05-02 Dib Limited Novel dosage form
US5178868A (en) * 1988-10-26 1993-01-12 Kabi Pharmacia Aktiebolaq Dosage form

Also Published As

Publication number Publication date
FR2386316A1 (fr) 1978-11-03
CH636276A5 (de) 1983-05-31
IT1109132B (it) 1985-12-16
AU3426778A (en) 1979-09-20
FR2386316B1 (enExample) 1983-04-08
JPS53124611A (en) 1978-10-31
SE7803690L (sv) 1978-10-08
IT7867760A0 (it) 1978-04-06
JPS6011887B2 (ja) 1985-03-28
AU515935B2 (en) 1981-05-07
DE2814709A1 (de) 1978-10-12
CA1098442A (en) 1981-03-31
GB1556149A (en) 1979-11-21
DE2814709C2 (enExample) 1990-07-12
US4160452A (en) 1979-07-10

Similar Documents

Publication Publication Date Title
SE435897B (sv) Forfarande for tillverkning av en osmotiskt driven avgivningsanordning
EP0180708B1 (en) Osmotic drug delivery device
CA1194797A (en) Sustained release oral medicinal delivery device
EP0040457B1 (en) Agent dispenser with microporous releasing diffusor
JPS61185272A (ja) 脂質浸透ポンプ
US4439196A (en) Osmotic drug delivery system
US4320759A (en) Dispenser with diffuser
US4016880A (en) Osmotically driven active agent dispenser
US4886668A (en) Multiparticulate controlled porosity osmotic pump
US4207890A (en) Drug-dispensing device and method
SE440724B (sv) Forfarande for framstellning av en osmotiskt driven avgivningsanordning
KR950013749B1 (ko) 미소환제로된 약물 방출 조성물
US4278087A (en) Device with integrated operations for controlling release of agent
US4475916A (en) Osmotic drug delivery system
EP0010876A1 (en) Osmotically driven active agent dispenser
JPS61249916A (ja) 不活性なコア部を有する浸透圧利用薬剤投与具
KR100677837B1 (ko) 약리학적으로 활성이 있는 물질 또는 이와 다른 물질을 2상 방출하기 위한 필름 형태의 약제
SE503471C2 (sv) Osmotisk dosform innehållande isradipin
IE44450B1 (en) Osmotically driven dispenser and process for making same
JPH02174713A (ja) 非対称薄膜を含んで成る薬剤等供給装置
JPS6058724B2 (ja) 浸透性投薬器
SE503508C2 (sv) Dosform för avgivande av diltiazem
CA1320885C (en) Controlled porosity osmotic pump
EP0365947A1 (en) Novel dosage form
JPH025978A (ja) 徐放デバイス

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 7803690-2

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 7803690-2

Format of ref document f/p: F